Although targeting the estrogen receptor (ER) or epithelia growth factor receptor (EGFR) signaling is a foremost strategy for breast cancer therapy, emerging data shows that the Hippo pathway promotes the breast cancer progression in various aspects, including cancer cell proliferation, migration, evasion and most importantly therapy resistance (Lamar et al., 2012; Wu and Yang, 2018). This evidence concerns the gene ESR1 and breast carcinoma.